Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials – Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease


BACKGROUND

CROSSWALK-a and CROSSWALK-c are two randomized, double-blind, placebo-controlled studies that are evaluating small-volume subcutaneous injection after an initial intravenous loading dose

CROSSWALK-a

- The primary objective of CROSSWALK-a is to evaluate safety and efficacy of crovalimab vs placebo up to 48 weeks (Table 2 and Figure 2). The study is currently actively enrolling in 7 countries (Figure 2).

CROSSWALK-c

- The primary objective of CROSSWALK-c is to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab as adjunct therapy in preventing VOEs

POSSIBLE CONFIDENTIAL EXCERPT

POSSIBLE CONFIDENTIAL EXCERPT

Table 3. Additional key eligibility criteria for CROSSWALK-c:

- Participation in a chronic transfusion program and/or planning to undergo an exchange procedure within 3 months prior to VOE presentation
- History of hemostatic imbalance and/or end-organ damage
- Active systemic bacterial, viral, or fungal infection ≤14 days before the first dose
- Severe or unstable medical conditions requiring hospitalization
- History of prior SCD hospitalization ≤21 days before the first dose

Table 4. Key endpoints and objectives in CROSSWALK-c:

Objectives

- For more information about CROSSWALK-a, please visit http://crosswalk-a.com
- For more information about CROSSWALK-c, please visit http://crosswalk-c.com

Acknowledgements

REFERENCES

Disclosures

Presented at the 2023 American Society of Hematology Annual Meeting | December 9–12, 2023

FOR ADDITIONAL INFORMATION

FOR ADDITIONAL INFORMATION

#1158